# What AI Protein Design Means for Biotech Valuations

*When Stanford compresses drug discovery from years to weeks, who wins?*

---

## The Signal

Last week, Stanford researchers published something that should make biotech investors pay attention: they used generative AI to design tumor-targeting proteins — and did it in **two weeks** instead of the typical two-to-five years.

The numbers are striking:
- **2,600 novel protein designs** generated in 30 hours
- Viable candidates identified in **under 14 days**
- Validated at atomic scale with high specificity, minimal off-target effects

This isn't a theoretical exercise. The proteins were tested against real cancer cells. They worked.

But here's what most coverage missed: the breakthrough wasn't just "AI is fast." It was a design insight. The team constrained their AI to work only with rigid α-helical protein scaffolds — a counterintuitive choice that actually *improved* computational accuracy and reduced unwanted binding.

**Smart constraints beat open-ended generation.** That's a principle worth remembering.

---

## The Connection

Drug discovery has a brutal economic profile:
- Average time to market: **10-15 years**
- Average cost per approved drug: **$1-2 billion**
- Success rate from Phase 1 to approval: **~10%**

If AI can compress the discovery phase by even 50%, the math changes dramatically. We're talking about:
- Faster iteration cycles
- Lower capital requirements per candidate
- More shots on goal with the same R&D budget

The companies positioned to capture this shift fall into three buckets:

**1. AI-native drug discovery platforms**
- Recursion Pharmaceuticals (RXRX) — NVIDIA-backed, partnerships with Sanofi/Roche/Genentech
- Insitro, Relay Therapeutics, Schrödinger

**2. Big pharma integrators**
- Eli Lilly just announced a **$1 billion AI co-innovation lab** with NVIDIA
- Roche, Novartis, and others quietly building internal capabilities

**3. Infrastructure picks-and-shovels**
- NVIDIA (simulation, training compute)
- Cloud providers with biotech-specific tooling

---

## The Trade

**The high-conviction play:** Recursion (RXRX) is at an inflection point.

For years, it was dismissed as a "science project" — impressive technology, unclear commercial path. That's changing:
- Clinical programs advancing
- Revenue from pharma partnerships
- NVIDIA's backing (BioHive-2 supercomputer) signals serious infrastructure

The stock is volatile. It's pre-profitability. It's not for everyone.

But if the AI-biotech thesis plays out over 3-5 years, RXRX is one of the purest expressions of it in public markets.

**The safer play:** Eli Lilly (LLY) gives you exposure through a profitable, diversified pharma company that's aggressively investing in AI capabilities. Less upside, less risk.

**The infrastructure play:** NVIDIA (NVDA) benefits regardless of which drug discovery company wins. They sell the shovels.

---

## The Bigger Picture

This protein design breakthrough is a data point in a larger trend: **AI is becoming the bottleneck-breaker for capital-intensive R&D.**

We've seen it in chip design (NVIDIA uses AI to design its own chips). We're seeing it in materials science. Now it's hitting drug discovery.

The pattern: industries with long development cycles, high failure rates, and expensive iteration are exactly where AI creates the most leverage.

If you're looking for the next wave of AI value creation, follow the constraints. Where are the expensive bottlenecks? Where does iteration cost millions instead of dollars?

That's where AI will matter most.

---

*This is not financial advice. I'm sharing how I think about connecting research to markets. Do your own work.*

---

**About:** I'm a finance professional who reads research papers for fun. This newsletter finds investment signals in non-obvious places — where the science people and the money people rarely overlap.

*Subscribe for weekly posts at the intersection of research and returns.*
